Anti-Tuberculosis Therapy in The Drug Resistant Tuberculosis Patients of Kashmir Valley
Life Sciences-Pulmonary Medicine
DOI:
https://doi.org/10.22376/ijlpr.2023.13.1.L281-292Keywords:
Drug Resistant, Tuberculosis, Regimen, Treatment, KashmirAbstract
Drug-resistant tuberculosis (DR-TB) strains are a significant threat to global TB control. Due to a lack of resources and inadequate healthcare infrastructure, it is difficult to identify and monitor drug resistance situations in low and middle-income nations. The study aimed to evaluate the anti-tuberculosis therapy regimen in drug-resistant tuberculosis patients of the mountainous valley of Kashmir. The current study was carried out at Government Medical College, Department of Pulmonary Medicine, Chest Diseases Hospital (CDH), Srinagar, Kashmir. A total of 1100 suspected tuberculosis subjects were included in the study, and out of 1100 TB subjects, 195 were documented medication resistance cases. Of the total 1100 Line Probe Assay (LPA) tests done, 69 (6.2%) such samples in the Tuberculosis band were absent. Of the real samples tested by LPA, Tuberculosis band (TUB) was present in 1031 samples (93.7%), of which 24 (2.3%) were multidrugresistant (MDR), 121 (11.7%) were rifampicin mono-resistant, 42 (4.0%) were isoniazid mono-resistant, 8 (0.77%) were extensively drugresistant (XDR), and 836 (81%) samples were pan-sensitive. Smoking remained an independent risk factor for poor treatment outcomes in the multivariate analysis (p-value = 0.014, OR = 4.356, 95% CI [1.425–12.45]). This study found a low incidence of Drug-Resistant Tuberculosis (DR-TB). Most of the cases were resistant to first-line anti-tuberculosis drugs. Special attention should be paid to high-risk DR-TB patients to improve treatment results even further. Further studies are recommended with a large sample size.
References
Thakur G, Thakur S, Thakur H. Status and challenges for tuberculosis control in India - Stakeholders’ perspective. Indian J Tuberc. 2021 Jul;68(3):334-9. doi: 10.1016/j.ijtb.2020.10.001, PMID 34099198.
Sakamoto H, Lee S, Ishizuka A, Hinoshita E, Hori H, Ishibashi N et al. Challenges and opportunities for eliminating tuberculosis - leveraging political momentum of the UN high-level meeting on tuberculosis. BMC Public Health. 2019 Jan 16;19(1):76. doi: 10.1186/s12889-019-6399-8, PMID 30651096.
India TB. Revised national tuberculosis control programme annual status report; 2017.
Aijaz NP, Naveed NS, Sandeep T, Ruqeya N, Bashir H. Study of Prevalence of tuberculosis Disease in the north Indian Subcontinent Kashmir Valley: A cross-sectional study. J ClinDiagn Res. 2022 Jan;16(1):10-4.
IIPS. National family health survey - 4. 2015-16: India fact sheet;2015:8.
Vijay KC, Kumary S. Global health governance and the end TB strategy: an optimistic post-2015 development agenda. Glob J Med Public Health. 2015;4:1-3.
Mayurnath S, Anantharaman DS, Baily GV, Radhamani MP, Vallishayee RS, Venkataraman P, et al. Tuberculosis prevalence survey in Kashmir valley. Indian J Med Res. 1984;80:129-40. PMID 6439632.
Dhamnetiya D, Patel P, Jha RP, Shri N, Singh M, Bhattacharyya K. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age-period-cohort analysis. BMC Pulm Med. 2021;21(1):375. doi: 10.1186/s12890-021-01740-y, PMID 34784911.
Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. ClinMicrobiol Rev. 2003 Jul;16(3):463-96. doi: 10.1128/CMR.16.3.463-496.2003, PMID 12857778.
World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
World Health Organization. Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis. 2018 update. Geneva: WHO press; 2018.
Mase SR, Chorba T. Treatment of drug-resistant tuberculosis. Clin Chest Med. 2019 Dec;40(4):775-95. doi: 10.1016/j.ccm.2019.08.002, PMID 31731984.
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim S. J, Reniero. A, Hoffner, S, Rieder, H. L, Binkin, N, Dye, C, Williams, R, &Raviglione, M. C. Global trends in resistance to anti-tuberculosis drugs. The New England Journal of Medicine (2001)., 344(17), 1294-303.
Eker B, Ortmann J, Migliori G. B, Sotgiu, G, Muetterlein, R, Centis, R, Hoffmann, H, Kirsten, D, Schaberg, T, Ruesch-gerdes, S, & Lange, C. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerging Infectious Diseases (2008)., 14(11), 1700-6.
Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring HarbPerspect Med. 2015 Apr 27;5(9):a017863. doi: 10.1101/cshperspect.a017863, PMID 25918181.
Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). 2014 Jul 2;3(3):317-40. doi: 10.3390/antibiotics3030317, PMID 27025748.
Prasad R, Gupta N, Banka A. Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: principles of management. Lung India. 2018 Jan-Feb;35(1):78-81. doi: 10.4103/lungindia.lungindia_98_17, PMID 29319042.
Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. J Glob Infect Dis. 2011 Apr;3(2):143-50. doi: 10.4103/0974-777X.81691, PMID 21731301.
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLOS ONE. 2011 Mar 30;6(3):e18327. doi: 10.1371/journal.pone.0018327, PMID 21479171.
Riaz M, Mahmood Z, Javed MT, Javed I, Shahid M, Abbas M et al. S. Drug resistant strains of Mycobacterium tuberculosis identified through PCR-RFLP from patients of Central Punjab, Pakistan. Int J ImmunopatholPharmacol. 2016 Sep;29(3):443-9. doi: 10.1177/0394632016638100, PMID 27069023.
Ahmed S, Shukla I, Fatima N, Varshney SK, Shameem M, Tayyaba U. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India. Int J Mycobacteriol. 2018;7(4):315-27. doi: 10.4103/ijmy.ijmy_98_18, PMID 30531028.
WHO. Definitions and reporting framework for tuberculosis – 2013 revision (updated 2014). Geneva: Switzerland World Health Organization; 2013.
Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Indian J Chest Dis Allied Sci. 2007;49:75.
World Health Organization. The global plan to stop TB: 2015–2020. Geneva: World Health Organization; 2019.
Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. EurRespir J. 2017 Mar 22;49(3):1602308. doi: 10.1183/13993003.02308-2016, PMID 28331043.
Verma R, Khanna P, Mehta B. Revised national tuberculosis control program in India: the need to strengthen. Int J Prev Med. 2013 Jan;4(1):1-5. PMID 23413398.
Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: current evidence on diagnosis & management. Indian J Med Res. 2017 Mar;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16, PMID 28749390.
Charan J, Tank N, Reljic T, Singh S, Bhardwaj P, Kaur R et al. Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis. J Family Med Prim Care. 2019 Oct 31;8(10):3191-201. doi: 10.4103/jfmpc.jfmpc_542_19, PMID 31742141.
Tola H, Holakouie-Naieni K, Mansournia MA, Yaseri M, Gamtesa DF, Tesfaye E et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study. BMJ, (Open). 2021 Aug 10;11(8):e040862. doi: 10.1136/bmjopen-2020-040862, PMID 34376436.
Bastos ML, Cosme LB, Fregona G, do Prado TN, Bertolde AI, Zandonade E, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718. doi: 10.1186/s12879-017-2810-1, PMID 29137626.
McQuaid CF, Horton KC, Dean AS, Knight GM, White RG. The Risk of multidrug or rifampicin –resistance in men versus women with TB. EurRespir J. 2020.
Baluku JB, Mukasa D, Bongomin F, Stadelmann A, Nuwagira E, Haller S et al. Gender differences among patients with drug resistant tuberculosis and HIV co-infection in Uganda: a countrywide retrospective cohort study. BMC Infect Dis. 2021;21(1):1093. doi: 10.1186/s12879-021-06801-5, PMID 34689736.
SeliemIbrahiem MI. Detection of extensively drug resistant [tuberculosis MD thesis]. Faculty of Medicine, Alexandria University; 2012.
Gomes M, Correia A, Mendonça D, Duarte R. Risk factors for drug-resistant tuberculosis. J Tuberc Res. 2014;02(3):111-8. doi: 10.4236/jtr.2014.23014.
Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia–an observational cohort study. Thorax. 2015;70(12):1181-8. doi: 10.1136/thoraxjnl-2015-207374, PMID 26506854.
Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One. 2009;4(2):e4370. doi: 10.1371/journal.pone.0004370, PMID 19190774.
Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995;333(14):907-11. doi: 10.1056/NEJM199510053331404, PMID 7666876.
Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001. Int J Tuberc Lung Dis. 2003;7(2):124-31. PMID 12588012.
Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008;12(10):1182-9. PMID 18812049.
Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004;8(3):361-8. PMID 15139476.
Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Ba Z, Naing NN. Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia. Malays J Med Sci. 2016;23(4):17-25. doi: 10.21315/mjms2016.23.4.3, PMID 27660541.
Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290-5. doi: 10.1086/522537, PMID 17968823.
MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014 Feb 1;92(2):126-38. doi: 10.2471/BLT.13.124800, PMID 24623906.
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798-807. doi: 10.1016/S0140-6736(10)60492-8, PMID 20488525.
Jeon CY, Hwang SH, Min JH, Prevots DR, Goldfeder LC, Lee H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46(1):42-9. doi: 10.1086/524017, PMID 18171212.
Escudero E, Peña JM, Alvarez-Sala R, Vázquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. Int J Tuberc Lung Dis. 2006;10(4):409-14. PMID 16602405.
Rao NA, Irfan M, Mahfooz Z. Treatment outcome of multidrug resistant tuberculosis in a tertiary care hospital in Karachi. J Pak Med Assoc. 2009;59(10):694-8. PMID 19813685.
Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006;10(6):649-55. PMID 16776452.
Rodriguez M, Monedero I, Caminero JA, Encarnación M, Dominguez Y, Acosta I, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17(4):520-5. doi: 10.5588/ijtld.12.0481, PMID 23485386.
Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLOS ONE. 2007;2(11):e1126. doi: 10.1371/journal.pone.0001126, PMID 17987113.
Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10(4):402-8. PMID 16602404.
Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, El Rhazi K, et al. association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011;15(6):838-43. doi: 10.5588/ijtld.10.0437, PMID 21575308.
de Souza ER, Franco LG, MeirelesCde C, Ferreira VT, Dos Santos NC. Psychological distress among civilian police: a gender-based analysis. Cad SaûdePûblica. 2007;23(1):105-14. doi: 10.1590/s0102-311x2007000100012. PMID 17187109.
Baluku JB, Nakazibwe B, Naloka J, Nabwana M, Mwanja S, Mulwana R et al. Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study. J ClinTuberc Other Mycobact Dis. 2021 Jan 27;23:100221. doi: 10.1016/j.jctube.2021.100221, PMID 33553682.
El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: multicentric prospective study. BMC Infect Dis. 2019 Apr 11;19(1):316. doi: 10.1186/s12879-019-3931-5, PMID 30975090.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577-87. doi: 10.1056/NEJMoa1407426, PMID 25196020.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599-608. doi: 10.1056/NEJMoa1314210, PMID 25337749.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588-98. doi: 10.1056/NEJMoa1315817, PMID 25337748.
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575-80. doi: 10.1016/S0140-6736(06)69573-1, PMID 17084757.
Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Alffenaar JC. Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. Int J Mycobacteriol. 2016;5;Suppl 1:S44-5. doi: 10.1016/j.ijmyco.2016.07.003, PMID 28043603.
van Altena R, Akkerman OW, Alffenaar J-WC, Kerstjens HAM, Magis-Escurra C, Boeree MJ, et al. Shorter Treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. EurRespir J. 2016;48(6):1800-2. doi: 10.1183/13993003.01208-2016, PMID 27824604.
Akkerman OW, Grasmeijer F, De Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, et al. Cross border, highly individualized treatment of a patient with challenging extensively drug-resistant tuberculosis. EurRespir J. 2018;51(3):3. doi: 10.1183/13993003.02490-2017, PMID 29419442.
Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72-82. doi: 10.1086/594126, PMID 19046064.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Aijaz Nabi Puttoo, Sandeep Tripathi, Naveed Nazir Shah, Ruqeya Nazir, Haamid Bashir, Aaliya Mohi-uD-Din Azad, Rehana Kauser, Inam-Ul-Haq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
